Navigation Links
BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
Date:9/11/2008

NOVATO, Calif., Sept. 11 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Joshua Grass, Vice President of Business and Corporate Development of BioMarin, will present a company update at the Merrill Lynch Global Pharmaceutical Conference in London on Thursday, September 18, 2008 at 10:35 a.m. BST.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please vi
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
2. BioMarin to Present at the Citi Biotech Day
3. BioMarin Announces Roll-Out of National PKU Registry
4. BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET)
5. BioMarin to Present at the Collins Stewart Growth Conference
6. SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive Procurement
7. BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
8. BioMarin to Host Research and Development Day June 5th
9. BioMarin to Present at the Bank of America Healthcare Conference
10. BioMarin Announces First Quarter 2008 Financial Results
11. BioMarin to Present at the Morgan Stanley Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... been honored for its commitment to sustainability with inclusion on ... is the highest ranked healthcare equipment company among the Corporate ... the World Economic Forum at Davos, Switzerland ...
(Date:1/22/2015)... N.J. , Jan. 22, 2015  Derma Sciences, ... regeneration company focused on advanced wound care, announces ... placental tissues, have been added to the Premier, ... increases the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® ...
(Date:12/24/2014)... SPRING, Md. , Dec. 24, 2014  United Therapeutics ... Medtronic, Inc. (NYSE: MDT ) has submitted ... Drug Administration (FDA) for the use of Medtronic,s SynchroMed ... newly developed catheter) for use with United Therapeutics, Remodulin ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... HGS product sales achieved with delivery of ABthrax(TM) to U.S. ... cash balance of $397 million as of March 31, up ... for second Phase 3 trial of Albuferon (R) ... fall 2009 - - Initiation of Syncria (R) ...
... RICHMOND, Calif., April 29 Sangamo BioSciences, Inc. ... success of its zinc finger DNA-binding protein (ZFP) ... Nature by licensing partner Dow AgroSciences ... technology for the efficient generation of maize plants ...
... , ... Austin, Texas (PRWEB) April 29, 2009 -- ... storing and distributing content, today announced the release of CAStor 3.0, ... virtual CAStor nodes in a single, physical server chassis. CAStor Cluster ...
Cached Biology Technology:Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 2Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 3Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 4Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 5Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 6Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 7Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 8Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 9Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 10Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species 2Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species 3Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species 4Caringo Delivers Storage Cluster in a Box with CAStor 3.0 2
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role in ... – the medical term for high blood pressure – was ... the inflatable cuff that,s used in measuring blood pressure was ... nothing new about hypertension, its triggers and its effects. In ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: you desperately ... your password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital infrastructure security ... end to the frustration that comes with usernames, passwords and PINs ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest Baptist ... building for its School of Medicine. Funding for this $50 ... that will be publicly launched next summer. ... 60 series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... flu viruses that infect birds and humans, a discovery that ... and aid in the development of vaccines against a deadly ... to infect humans depends on whether it can bind to ... respiratory cells. Now that we know what to look ...
... Diego has become the first campus on the West Coast ... voluntary, legally binding trading system to reduce emissions of greenhouse ... the nation to join the climate exchange. Joining the ... conserve energy and reduce greenhouse gases (GHG). Trading in GHG ...
... Ohio State University will battle for the BCS National ... but if the game was held in the Louisiana ... Louisianas wetlands are being lost at the rate of ... against this rapid destruction, the two universities joined forces ...
Cached Biology News:MIT finds key to avian flu in humans 2MIT finds key to avian flu in humans 3UC San Diego begins trading greenhouse gas credits on Chicago Climate Exchange 2LSU and Ohio State battle on football field, collaborate in research field 2
For the quantitative determination of canine Interferon gamma,(IFN-γ) concentrations in cell culture supernates, serum and,plasma....
Request Info...
Homo sapiens olfactomedin 1, transcript variant 3...
Component of GELase™ Agarose Gel-Digesting Preparation. 1 ml of 50X Buffer is sufficient for replacing the buffer in at least 5 g of gel....
Biology Products: